TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
REPL

Replimune Group Inc

Healthcare · Biotechnology

13.10$ +1.6% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Balance Sheet

Replimune Group Inc (REPL) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 252 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet REPL
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
562 533 488 535 498 604 551 470 389 334 332 252
508 479 434 480 443 548 496 413 334 280 279 201
76 98 74 152 113 172 111 97 102 123 209 185
497 466 421 469 432 537 484 403 324 269 269 195
2.9 4.3 4.9 4.9 2.0 3.1 3.7 1.8 1.8 3.0 1.6
-0.4
97 111 113 109 117 121 135 133 126 123 166 147
40 39 40 36 44 48 62 60 53 50 58 38
3.8 3.9 3.9 3.9 4.0 3.9 4.0 4.0 4.1 4.1 4.0 4.0
4.4 3.9 2.6 0.9 8.4 7.2 12 15 6.4 5.6 6.7 4.3
29 44 45 45 46 46 46 47 47 48 83 84
465 422 375 426 381 482 416 337 263 211 166 106
-595 -646 -701 -755 -808 -874 -949 -1,035 -1,118 -1,189 -1,263 -1,332
67 67 61 69 79 83 81 92 92 92 93 97

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?